Genentech announced yesterday that the US Food and Drug Administration approved tocilizumab (Actemra) for the treatment of Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD), specifically indicated for the slowing the rate of decline in pulmonary function in adults SSc-ILD.
Tocilizumab is the first biologic, but second drug (following ninteninib), to be approved to curtail the worsening of SSc-ILD.Read Article
The NEJM has published the results of the ACCT-2 Study, a double-blind, randomized, placebo-controlled trial evaluating baricitinib, an inhibitor of Janus kinase 1 (JAK1) and JAK2, plus remdesivir in hospitalized adults with Covid-19. The primary outcome was the time to recovery. The key secondary outcome was clinical status at day 15.Read Article
Analysis of the NHANES population survey data shows weight gain during adulthood increases the risk of gout and that maintaining normal weight could reduce the overall gout risk by nearly 33%.
Obesity and gout have long been linked, but the the influence of weight changes during adulthood has not been examined.Read Article